Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction.
Lilliu
H
H
CLP Santé, Paris, France.
Brun
C
C
Le Pen
C
C
Büchler
M
M
Al Najjar
A
A
Reigneau
O
O
Lebranchu
Y
Y
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000191:economics / Q000627:therapeutic use*; D000077552:Basiliximab; D003363:Cost Control; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005602:France; D006760:Hospitalization / Q000191:economics; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000191:economics / Q000453:epidemiology; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab